The Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) for the treatment of adults with previously treated locally advanced or metastatic IDH1-mutated cholangiocarcinoma (CCA), a ...
Voranigo and Temodar combination showed no serious side effects or dose-limiting toxicities in IDH1/2-mutant glioma patients. Treatment-emergent side effects led to dose reductions in 42.9% of ...
The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described isocitrate dehydrogenase (NADP) cytoplasmic (IDH1; PICD; IDP) (mutant) inhibitors reported to be useful for the ...
Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...
A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease This retrospective analysis ...
The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback